-The Hindu Despite government programmes, nutrition supplements for women and children are not to be found in Jharkhand’s villages More than two years after she gave birth to her youngest daughter, Shanti Oraon, an adivasi farmer in Bhandara village, Khunti district has been unable to resume working in the fields. “She has breathing trouble, and could not start walking even after she turned two and a half years old. I must stay...

-The Economic Times Pharmaceutical multinationals have begun using the Right to Information law to launch pre-emptive legal action against local generic players to protect the market of patented drugs and delay the entry of low cost generic medicines in the 60,000-crore domestic drug market. MNCs are using such information to sue generic firms even at a stage when their marketing approval is still pending or during the few months' window between the...

-The Times of India MUMBAI: The Union government and regulatory bodies appear to be serious in ending the pharma-doctor nexus and curb unethical marketing practices. In its latest effort, the Medical Council of India has directed doctors, hospitals and medical colleges to prescribe generic medicines as far as possible. generic medicines are more affordable versions of branded medicines sold by companies. In its directive dated January 21 to the principals of medical...

-The Times of India The government is all set to crack the whip on India's shameful pharma-doctor nexus. The National Development Council (NDC), led by Prime Minister Manmohan Singh, will meet on December 27 to discuss bringing a legislation requiring drug companies to mandatorily disclose payments made to doctors for research, consulting, lectures, travel and entertainment. Doctors involved in ghost writing to promote pharma products will also be disqualified. The official NDC document...

-The Economic Times The Union Cabinet has okayed a new price-control formula for pharmaceuticals, which seeks to cap prices at the arithmetic average of all drugs with more than 1% market share in any therapeutic segment that is to be brought under price control. Given that the existing system of fixing prices of select drugs is on the basis of costs, which is rigid, intrusive and prone to manipulation as well,...